ARAKODA

Peak

tafenoquine

NDAORALTABLETPriority Review
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
12

Mechanism of Action

8-aminoquinoline antimalarial drug [see Microbiology ()] .

Clinical Trials (5)

NCT06666491Phase 3Recruiting

An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older

Started Nov 2024
300 enrolled
Malaria, Vivax
NCT02802501Phase 3Completed

Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria

Started Apr 2018
150 enrolled
Malaria, Vivax
NCT02563496Phase 2Completed

A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria

Started Feb 2017
60 enrolled
Malaria, Vivax
NCT02751294Phase 1Completed

A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution

Started May 2016
14 enrolled
Malaria, Vivax
NCT02658435Phase 1Completed

Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)

Started Feb 2016
486 enrolled
Malaria, Vivax

Loss of Exclusivity

LOE Date
Dec 2, 2035
118 months away
Patent Expiry
Dec 2, 2035

Patent Records (3)

Patent #ExpiryTypeUse Code
10342791
Dec 2, 2035
U-2582
10888558
Dec 2, 2035
U-2582
11744828
Dec 2, 2035
U-2582